FOR SUPPORT, CALL 1-866-APF-3635 (273-3635)
Porphyria Post
COVID-19 Updates on the APF Website
The APF is working hard with the Porphyrias Consortium to make sure that our community is kept up-to-date on the latest COVID-19 news - as it pertains to patients with porphyria.
We have dedicated a special section of our website to COVID-19 updates and information.
Click Here to Access the APF COVID-19 Web Page
Clinuvel To Launch SCENESSE® In USA In April
CLINUVEL PHARMACEUTICALS LTD has announced plans to launch its novel drug SCENESSE® (afamelanotide) ahead of schedule in the USA, with the first patient to be treated as early as 15 April 2020.
The following are excerpts from a press release:
USA DISTRIBUTION SCENESSE® The distribution of SCENESSE® is planned in three phases. During Phase I, three selected hospitals and medical centers will be able to provide treatment to EPP patients. For Phase II, Medicare-Medicaid will need to complete its review of the SCENESSE® dossier and provide an opinion on National and Local Coverage for the treatment, as to be confirmed by the Centers for Medicare & Medicaid Services. The last phase will consist of direct distribution of the drug to a target maximum of 30 centers who will be trained and accredited by CLINUVEL.
INSURANCE COVERAGE SCENESSE® During the first phase of distribution commencing 15 April 2020, patients will be able to receive treatment under Prior Authorization [PA]. PA is a decision by a payor that a healthcare service, treatment plan, prescription drug, or durable medical equipment is medically necessary and is included in a member’s (patient’s) coverage.
CLINUVEL CO-PAYMENT SAVINGS PROGRAM CLINUVEL will establish for American EPP patients a CLINUVEL Co-Payment Savings Program. Individual applications will need to be made, whereby terms & conditions will apply to each patient on a case by case basis. EPP patients with commercial or private health insurance may be eligible, depending on the terms of each insurance policy. Reference is made to the Power Point slide deck released concomitantly today.
The APF has received your many questions regarding this press release. We are working with Clinuvel for responses. Please continue to email your questions to the APF at: kristen@porphyriafoundation.org
You aren’t alone! Many of our members are isolated at home, possibly away from loved one and medical professionals. However, we can come together as partners in this time of need. During the COVID-19,the APF has created a simple way to feel less alone and to connect with others in our community through Porphyria Partners. No social media required, just a willingness to check in with another porphyria warrior each day.
If you are interested in being partnered with another person, please email general@porphyriafoundation.org or call 866-APF-3635 with your name and email address. We will connect you with another another member via email. We ask that you make contact with each other and check in with each other each day in the best way for each of you.
We look forward to hearing from you!
Get Involved
Contact Information
Is your contact information up to date?
If not please give us a call @ 866-APF-3635 or Email to general@porphyriafoundation.org
American Porphyria Foundation| 1.866.APF.3635 | porphyriafoundation.org
STAY CONNECTED
"Remember....Research is the Key to Your Cure!"
